Fang Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fang Zhao has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Bo Yang
Department of Thoracic Surgery, Cangzhou Central Hospital, Cangzhou, People's Republic of China
1 shared publicationChunyuan He
Department of Hematology, Cangzhou Central Hospital, Cangzhou, People's Republic of China
1 shared publicationFenglei Yin
Department of Hematology, Cangzhou Central Hospital, Cangzhou, People's Republic of China
1 shared publicationJing Liu
Department of Hematology, Cangzhou Central Hospital, Cangzhou, People's Republic of China
1 shared publicationJuan Wang
Department of Hematology, Cangzhou Central Hospital, Cangzhou, People's Republic of China
1 shared publicationRui Zhang
Department of Hematology, Cangzhou Central Hospital, Cangzhou, People's Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 May 2018
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 12, 1525-1531
Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib
Purpose: Carfilzomib has been approved for use in relapsed and refractory multiple myeloma (RRMM). Cardiac toxicities have been reported with the use of carfilzomib. We aimed to determine the overall incidence and risk of cardiac toxicities in RRMM patients treated with carfilzomib using a meta-analysis. Methods: We searched several databases for relevant articles. Prospective trials evaluating carfilzomib in RRMM patients with adequate data on cardiac toxicities were included for analysis. Pooled incidence, Peto ORs, and 95% CIs were calculated according to the heterogeneity of selected studies. Results: A total of 2,607 RRMM patients from eight prospective trials were included. The pooled incidence of all-grade congestive heart failure (CHF) and ischemic heart disease (IHD) related to carfilzomib in RRMM patients was 5.5% (95% CI: 4.3%–6.9%) and 2.7% (95% CI: 1.1%–6.7%), respectively. In addition, the use of carfilzomib significantly increased all-grade (Peto OR 2.33, 95% CI: 1.56–3.48, ppp=0.30) and high-grade (Peto OR 1.41, 95% CI: 0.73–2.72, p=0.31) IHD in RRMM patients receiving carfilzomib. Conclusion: The use of carfilzomib in RRMM patients significantly increases the risk of developing CHF but not IHD. Clinicians should be cautious about the risk of CHF associated with carfilzomib to maximize the benefits and minimize the toxicities.
- 1 May 2018
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 12, 1525-1531
Open AccessIncidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib
Purpose: Carfilzomib has been approved for use in relapsed and refractory multiple myeloma (RRMM). Cardiac toxicities have been reported with the use of carfilzomib. We aimed to determine the overall incidence and risk of cardiac toxicities in RRMM patients treated with carfilzomib using a meta-analysis. Methods: We searched several databases for relevant articles. Prospective trials evaluating carfilzomib in RRMM patients with adequate data on cardiac toxicities were included for analysis. Pooled incidence, Peto ORs, and 95% CIs were calculated according to the heterogeneity of selected studies. Results: A total of 2,607 RRMM patients from eight prospective trials were included. The pooled incidence of all-grade congestive heart failure (CHF) and ischemic heart disease (IHD) related to carfilzomib in RRMM patients was 5.5% (95% CI: 4.3%–6.9%) and 2.7% (95% CI: 1.1%–6.7%), respectively. In addition, the use of carfilzomib significantly increased all-grade (Peto OR 2.33, 95% CI: 1.56–3.48, ppp=0.30) and high-grade (Peto OR 1.41, 95% CI: 0.73–2.72, p=0.31) IHD in RRMM patients receiving carfilzomib. Conclusion: The use of carfilzomib in RRMM patients significantly increases the risk of developing CHF but not IHD. Clinicians should be cautious about the risk of CHF associated with carfilzomib to maximize the benefits and minimize the toxicities.